Definium Therapeutics CEO Robert Barrow received 40,000 shares at $0 on Sept. 2, then sold 19,023 shares at $37.94 per share on Sept. 3. His reported holdings stood at 1,513,663 shares after the award and 1,494,640 after the sale, giving investors two distinct ownership changes to track.
Key Highlights
- Robert Barrow sold 19,023 Definium Therapeutics shares at $37.94 per share on Sept. 3.
- Barrow’s reported holding stood at 1,494,640 shares after the sale.
- The executive’s reported holding was 1,513,663 shares after the 40,000-share award.
Definium Therapeutics, Inc. (NASDAQ: DFTX) awarded Chief Executive Officer Robert Barrow 40,000 shares at $0 on Sept. 2. His reported ownership stood at 1,513,663 shares after the award, before a separate transaction the next day.
CEO Sale Follows Share Award
Barrow sold 19,023 Definium Therapeutics shares on Sept. 3 at $37.94 per share. The transaction followed the award dated Sept. 2. The sale involved the same executive named in the award. Definium Therapeutics identified Barrow as its chief executive officer in both transactions. The two transactions occurred on consecutive dates. The award covered 40,000 shares at $0 per share, while the later transaction involved a sale price of $37.94 per share. Barrow’s reported holding after the sale was 1,494,640 shares.
Reported Ownership After Both Transactions
The ownership figures show separate reported balances after each transaction. Barrow held 1,513,663 shares after the award and 1,494,640 shares after the sale. Those figures correspond to the two stages of the reported activity. Definium Therapeutics’ disclosure identifies both the number of shares involved and the per-share sale price.




Please wait processing your request...